Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Payables (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Payables for 6 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Payables rose 55.03% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 million through Dec 2025, up 55.03% year-over-year, with the annual reading at $2.5 million for FY2025, 55.03% up from the prior year.
  • Payables hit $2.5 million in Q4 2025 for Insight Molecular Diagnostics, up from $1.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $3.3 million in Q1 2022 to a low of $379000.0 in Q2 2024.
  • Historically, Payables has averaged $1.6 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Payables: surged 382.64% in 2021 and later tumbled 82.74% in 2024.
  • Year by year, Payables stood at $2.1 million in 2021, then crashed by 39.9% to $1.3 million in 2022, then dropped by 23.94% to $953000.0 in 2023, then skyrocketed by 72.19% to $1.6 million in 2024, then soared by 55.03% to $2.5 million in 2025.
  • Business Quant data shows Payables for IMDX at $2.5 million in Q4 2025, $1.1 million in Q3 2025, and $571000.0 in Q2 2025.